Press Release
MimiVax Announces New Investments to Support Clinical Development of SurVaxM in Glioblastoma
Buffalo, N.Y. · January 9, 2024
MimiVax, Inc., developer of SurVaxM, a survivin-targeted vaccine therapy for glioblastoma and other cancers, announced new investments from the venture philanthropy arms of leading brain tumor patient organizations, along with venture capital and private investors.
The investments — from the Brain Tumor Investment Fund (BTIF, an affiliate of the National Brain Tumor Society), the Sontag Innovation Fund, MEDA Angels, Varia Ventures and private investors — will support the ongoing Phase 2b clinical study, subsequent registration-related work, and preparation for commercialization of SurVaxM in newly diagnosed glioblastoma.
MimiVax is enrolling patients in the SURVIVE trial (NCT05163080), a randomized, blinded, placebo-controlled Phase 2b study of SurVaxM in newly diagnosed glioblastoma at 11 cancer centers across the United States. This follows the Phase 2a study published in the Journal of Clinical Oncology, which met its primary endpoint with a median overall survival of 25.9 months and found that 41% of patients receiving SurVaxM survived at least three years.
“We are honored to receive significant investments from the Brain Tumor Investment Fund, the Sontag Innovation Fund, MEDA Angels, Varia Ventures and our private investors,” said Michael J. Ciesielski, PhD, Chief Executive Officer. “Their confidence in our mission further propels our efforts to make a meaningful impact in the lives of those affected by brain tumors.”
About SurVaxM: SurVaxM is a first-in-class, patented immunotherapy targeting survivin, a cell-survival protein present in many forms of cancer. Delivered subcutaneously, it stimulates a patient’s own immune response to control tumor growth and help prevent disease recurrence.
About MimiVax: MimiVax, Inc. is a Delaware-incorporated, clinical-stage biotechnology company focused on immunotherapy research and clinical translation of new agents for cancer treatment, formed to develop and commercialize its lead candidate, SurVaxM.